Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy

Topoisomerase IIβ–Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane

Yi Lisa Lyu, John E. Kerrigan, Chao‐Po Lin et al. · Cancer Research · 2007 · 598 citations

Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity

Patrick W. Fisher, Fadi N. Salloum, Anindita Das et al. · Circulation · 2005 · 349 citations · Full text

Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.

K Tanabe, Yoji Ikegami, Ryoji Ishida et al. · PubMed · 1991 · 297 citations

Molecular Pharmacology, Medicinal Chemistry, Pharmaceutical Chemistry +14

Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187

Scott Classen, Stéphane Olland, James M. Berger · Proceedings of the National Academy of Sciences · 2003 · 259 citations · Full text

Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.

Ryoji Ishida, T Miki, Toshiharu Narita et al. · PubMed · 1991 · 195 citations

Chemoprevention Strategy, Antitumor Bis, Intracellular Topoisomerase Ii +23